March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma (FL)..
Ako ovo čitate, vi ili možda netko od vaših voljenih ste na putu na koji nitko ne planira krenuti – putu suočavanja s rakom. Razumijemo da je ovaj put ispunjen neizvjesnostima, strahovima i trenucima kada se osjeća..
Otkrijte znanost iza tretmana CAR T Cell terapijom u Indiji! Istražite kako ovaj revolucionarni tretman pretvara vaše imunološke stanice u borce protiv raka. Pročitajte naš blog sada kako biste saznali više o ovoj čudesnoj terapiji i kako ..
Have you ever wondered if there is a powerful way to fight cancer? Now just imagine if one day you found a ray of hope in your fight against cancer, a treatment that uses the power of your body's own immune system to target an..
Svibanj 2023.: Za odrasle pacijente s B-staničnim limfomom visokog stupnja (HGBL), koji nije drugačije specificiran (NOS), ili difuznim velikim B-staničnim limfomom (DLBCL) koji prethodno nisu bili na liječenju i koji imaju Međunarodni prognostički indeks.
SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the Na..
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T. According to stati..
Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma. In BRUIN (NCT03740529), an open-label, multicenter, single-arm trial of pirtobr..
Feb 2023: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) is approved by FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA was used to assess effectiveness in CLL/SLL patients who had not recei..
Studeni 2022.: Uprava za hranu i lijekove odobrila je kombinaciju doksorubicina, vinkristina, etopozida, prednizona i ciklofosfamida s brentuksimab vedotinom (Adcetris, Seagen, Inc.) za upotrebu kod djece i...